Disseminated castration‐resistant prostate cancer (CRPC) is a common disease in men that
is characterized by limited survival and resistance to androgen‐deprivation therapy. The …

Metastatic prostate cancer continues to pose a difficult therapeutic challenge. Prostate
cancer progression is associated with aberrant O-glycosylation of cancer cell surface …

Prostate cancer (PCa) is one of the most common causes of male cancer-related death in
Western nations. The cellular response to androgens is mediated via the androgen receptor …

Patterns of glycosylation are important in cancer, but the molecular mechanisms that drive
changes are often poorly understood. The androgen receptor drives prostate cancer (PCa) …

Prostate cancer is the most common cancer in men and it is estimated that over 350,000
men worldwide die of prostate cancer every year. There remains an unmet clinical need to …

Purpose: The majority of patients with prostate cancer who are treated with androgen-
deprivation therapy (ADT) will eventually develop fatal metastatic castration-resistant …

The precise molecular alterations driving castration-resistant prostate cancer (CRPC) are
not clearly understood. Using a novel network-based integrative approach, here, we show …

Steroid androgen hormones play a key role in the progression and treatment of prostate
cancer, with androgen deprivation therapy being the first-line treatment used to control …

Prostate cancer is the second most common cause of cancer-associated deaths in men and
signalling via a transcription factor called androgen receptor (AR) is an important driver of …

Lineage plasticity of prostate cancer is associated with resistance to androgen receptor (AR)
pathway inhibition (ARPI) and supported by a reactive tumor microenvironment. Here we …